Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2019-09-17 , DOI: 10.1111/jdi.13137
Megumi Yasuda ₁ , Katsumi Iizuka ₁ , Takehiro Kato ₁ , Yanyan Liu ₁ , Ken Takao ₁ , Kenta Nonomura ₁ , Masami Mizuno ₁ , Daisuke Yabe ₁

Affiliation

A 70‐year‐old woman with type 2 diabetes was admitted to Gifu University Hospital, Gifu, Japan, because of ketosis. She was diagnosed with type 2 diabetes at age 49 years and started insulin therapy at age 57 years, which restored glycemic control. Insulin therapy was discontinued and oral antidiabetes drugs, including sodium–glucose cotransporter 2 inhibitor dapagliflozin, were initiated at age 69 years. Thereafter, her bodyweight declined from 40.0 kg to 29.8 kg in 12 months; glycated hemoglobin remained >8.0%. On admission to our hospital, her laboratory tests and computed tomography scan showed ketosis, insulinopenia, and the presence of dehydration and bacterial pneumonia. She also lost substantial bodyweight and developed sarcopenia. The current case shows the importance of patient assessment before sodium–glucose cotransporter 2 inhibitor initiation in the elderly.

中文翻译：

患有 2 型糖尿病的瘦老年人的钠-葡萄糖协同转运蛋白 2 抑制剂和肌肉减少症：病例报告。

一名患有 2 型糖尿病的 70 岁女性因酮症入院于日本岐阜大学医院。她在 49 岁时被诊断出患有 2 型糖尿病，并在 57 岁时开始胰岛素治疗，血糖恢复了控制。 69 岁时，停止胰岛素治疗并开始口服抗糖尿病药物，包括钠-葡萄糖协同转运蛋白 2 抑制剂达格列净。此后12个月内，她的体重从40.0公斤下降到29.8公斤；糖化血红蛋白保持>8.0%。入院后，她的实验室检查和计算机断层扫描显示酮症、胰岛素减少、脱水和细菌性肺炎。她的体重也大幅下降，并出现了肌肉减少症。当前的病例显示了在老年人开始使用钠-葡萄糖协同转运蛋白 2 抑制剂之前进行患者评估的重要性。

更新日期：2019-09-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南